Merck (MRK) Receivables - Other (2012 - 2023)

Merck (MRK) has reported Receivables - Other for 6 consecutive years, with $473.0 million the latest figure, recorded in Q1 2023.

• On a quarterly basis, Receivables - Other fell 34.21% year-over-year to $473.0 million in Q1 2023; TTM through Mar 2023 was $473.0 million, a 34.21% decrease from a year earlier, with the FY2022 full-year figure at $511.0 million, down 46.99% from the prior year.
• Receivables - Other was $473.0 million for Q1 2023 at Merck, down from $511.0 million in the prior quarter.
• Over five years, Receivables - Other peaked at $1.6 billion in Q2 2021 and troughed at $473.0 million in Q1 2023.
• A 3-year average of $860.4 million and a median of $684.0 million in 2022 frame the typical range for Receivables - Other.
• Across the five-year window, Receivables - Other plunged 59.5% in 2022 and sank 34.21% in 2023, its largest moves.
• Over 3 years, Receivables - Other stood at $964.0 million in 2021, then slumped by 46.99% to $511.0 million in 2022, then slipped by 7.44% to $473.0 million in 2023.
• The last three Receivables - Other figures came in at $473.0 million (Q1 2023), $511.0 million (Q4 2022), and $567.0 million (Q3 2022), per Business Quant data.